In the past several years, there have been significant advances in the 
therapeutic arsenal of agents used to treat multiple myeloma (MM). Despite these 
advances, MM remains incurable. One of the most recent therapeutic advances is 
the development of targeted monoclonal antibodies (MoAbs). The MoAbs have 
significantly improved disease response rates, and extended survival in MM 
patients. In this review, we highlight the current US Food and Drug 
Administration approved MoAbs, namely, belantamab mafodotin, daratumumab, 
elotuzumab, and isatuximab. The mechanisms of action and pivotal clinical trials 
that led to US Food and Drug Administration approval of these agents and their 
current therapeutic use in the management of patients with MM are discussed in 
detail. Lastly, we describe several novel MoAbs under clinical investigation 
with potential for approval in the future.